Tenax Therapeutics (NASDAQ:TENX) Stock Rating Upgraded by Wall Street Zen

Tenax Therapeutics (NASDAQ:TENX) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts also recently issued reports on TENX. Evercore downgraded Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target on the stock. in a report on Tuesday, August 11th. Chardan Capital downgraded shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price for the company. in a research note on Tuesday, August 11th. Guggenheim lowered Tenax Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 31st. UBS Group downgraded Tenax Therapeutics to a “neutral” rating in a report on Monday, August 31st. Finally, Roth Capital set a $5.00 price target on shares of Tenax Therapeutics in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $14.00.

Tenax Therapeutics Stock Performance

TENX opened at $1.69 on Friday. The stock has a market capitalization of $63.24 million, a price-to-earnings ratio of -1.22 and a beta of 0.99. Tenax Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $19.40. The company has a fifty day moving average of $1.81 and a two-hundred day moving average of $9.74.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.04. On average, equities research analysts forecast that Tenax Therapeutics will post -1.38 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc bought 900,000 shares of Tenax Therapeutics stock in a transaction dated Thursday, September 3rd. The stock was bought at an average price of $1.78 per share, for a total transaction of $1,602,000.00. Following the purchase, the insider owned 6,524,151 shares of the company’s stock, valued at approximately $11,612,988.78. The trade was a 16.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have purchased 3,682,899 shares of company stock valued at $6,388,279. Company insiders own 10.81% of the company’s stock.

Hedge Funds Weigh In On Tenax Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in shares of Tenax Therapeutics by 1,005.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 22,667 shares of the specialty pharmaceutical company’s stock valued at $43,000 after acquiring an additional 20,616 shares in the last quarter. Alps Advisors Inc. increased its position in shares of Tenax Therapeutics by 82.8% during the 3rd quarter. Alps Advisors Inc. now owns 49,225 shares of the specialty pharmaceutical company’s stock valued at $93,000 after purchasing an additional 22,301 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in Tenax Therapeutics during the 3rd quarter valued at $94,000. Bank of America Corp DE lifted its position in Tenax Therapeutics by 391.2% in the 1st quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock valued at $297,000 after acquiring an additional 14,789 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Tenax Therapeutics during the 2nd quarter valued at about $485,000. 1.67% of the stock is owned by institutional investors and hedge funds.

More Tenax Therapeutics News

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax reported a third-quarter loss of $0.31 per share, narrower than analysts’ expected $0.35 loss. The company also said analyses of its LEVEL trial informed a predictive-enrichment strategy for the amended LEVEL-2 protocol, and that it has been granted a Type C meeting with the FDA. Tenax reports third-quarter results and corporate update
• Neutral Sentiment: The class action’s lead-plaintiff deadline is December 28, 2026. The court has not established that the allegations are true. Johnson Fistel investor alert
• Negative Sentiment: Investors’ attention is focused on a securities class action covering purchases from November 13, 2023, through August 7, 2026. The complaint alleges Tenax and certain executives made misleading statements about TNX-103’s clinical prospects; one notice says the company raised $134 million before its Phase 3 LEVEL trial missed its primary endpoint. The litigation creates uncertainty and could add legal costs, although the claims remain allegations. TENX shareholder alert and lawsuit allegations

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.